aleniglipron vs dulaglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

Next expected readout: September 2028 · NCT07654374 (registry estimate)

Reported efficacy

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)

Result source: NCT05762471

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: April 2027 · NCT07537088 (registry estimate)

Reported efficacy

Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)

Result source: NCT03495102

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalenigliprondulaglutide
HbA1c, change—Trial running · NCT07654374-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
Body weight, change (kg)—Trial running · NCT07654374-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
HbA1c below 7%—Trial running · NCT0765437475.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
Fasting plasma glucose, change—Trial running · NCT07654374-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
3-point MACE (% with event)—Trial running · NCT0765437412% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433

HbA1c, change

aleniglipron
—Trial running · NCT07654374
dulaglutide
-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410

Body weight, change (kg)

aleniglipron
—Trial running · NCT07654374
dulaglutide
-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410

HbA1c below 7%

aleniglipron
—Trial running · NCT07654374
dulaglutide
75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410

Fasting plasma glucose, change

aleniglipron
—Trial running · NCT07654374
dulaglutide
-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582

3-point MACE (% with event)

aleniglipron
—Trial running · NCT07654374
dulaglutide
12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo NCT05762471 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. aleniglipron: 0 of 4 rows · dulaglutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdulaglutide
Dropout rate
0.3%a
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
4.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.8%4.5 mg
NCT03495102 · Phase 3
10.9%3 mg
NCT03495102 · Phase 3
9.2%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
3.8%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
3.9%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
2.5%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
2.2%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.1%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
4.9%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
3.5%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
8%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
12.4%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
14.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
10.4%
NCT01769378 · Phase 3 · registry result, not featured evidence
9%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
9.7%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
10%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
9.2%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
5.1%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
16.7%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
1.7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%4.5 mg
NCT03495102 · Phase 3
1.1%3 mg
NCT03495102 · Phase 3
0.8%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
0%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
1.7%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
—1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.4%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
4%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
2.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.3%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.2%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
0.4%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
6%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
2.6%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
1.3%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
8.3%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
40.3%a
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%4.5 mg
NCT03495102 · Phase 3
7.3%3 mg
NCT03495102 · Phase 3
8.7%1.5 mg
NCT03495102 · Phase 3
21.4%1.5 mg
NCT01621178 · Phase 3
25.3%0.75 mg
NCT01621178 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
4%1.5 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
0%1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
0%0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
2.5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
0%
NCT03315780 · Phase 4 · registry result, not featured evidence
31.9%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
3.8%1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.6%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
5.6%1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
3.5%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
2.1%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
6%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
9.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
5.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
3.8%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.6%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.7%1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
—LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
3.9%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
8.9%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
9.1%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
0%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
nausea 14.9% (placebo 5.4%)
diarrhoea 13.5% (placebo 8.8%)
nasopharyngitis 11.4% (placebo 10.8%)
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
nasopharyngitis 27.1%
diarrhoea 12.2%
nausea 9.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5 mg
nausea 17.3%
diarrhoea 11.4%
vomiting 10.4%
NCT03495102 · Phase 3
3 mg
nausea 16.1%
diarrhoea 12.2%
vomiting 9.3%
NCT03495102 · Phase 3
1.5 mg
nausea 14.2%
diarrhoea 7.8%
vomiting 6.5%
NCT03495102 · Phase 3
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3
1.5 mg
diarrhoea 21.2% (placebo 13.7%)
headache 15.4% (placebo 9.8%)
nausea 15.4% (placebo 7.8%)
NCT02963766 · Phase 3
1.5 mg
diarrhoea 12% (placebo 13.7%)
nausea 12% (placebo 7.8%)
abdominal pain upper 10% (placebo 7.8%)
NCT02963766 · Phase 3
0.75 mg
vomiting 17.6% (placebo 3.9%)
diarrhoea 15.7% (placebo 13.7%)
headache 13.7% (placebo 9.8%)
NCT02963766 · Phase 3
0.75 mg
headache 10.2% (placebo 9.8%)
vomiting 8.2% (placebo 3.9%)
abdominal pain 6.1% (placebo 5.9%)
NCT02963766 · Phase 3
1.5 mg
gastritis 14.3%
dyslipidaemia 9.5%
nausea 9.5%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
anaemia 21.4%
gastritis 14.3%
dyslipidaemia 7.1%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 15.8% (placebo 30.8%)
abdominal discomfort 8.3% (placebo 12.8%)
constipation 6.7% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 28.3% (placebo 30.8%)
constipation 10.8% (placebo 12.8%)
abdominal discomfort 9.2% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
influenza 16.7% (placebo 0%)
decreased appetite 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 8.3%)
NCT03315780 · Phase 4 · registry result, not featured evidence
1.5 mg
nausea 22.3%
diarrhoea 18.9%
covid-19 15.1%
NCT04255433 · Phase 3 · registry result, not featured evidence
1.5 mg
constipation 12.5%
diarrhoea 10.2%
pyrexia 10%
NCT04809220 · Phase 3 · registry result, not featured evidence
0.75 mg
constipation 8.7%
nasopharyngitis 8.7%
covid-19 8.2%
NCT04809220 · Phase 3 · registry result, not featured evidence
1.5 mg
decreased appetite 22.2% (placebo 4.1%)
diabetic nephropathy 13.9% (placebo 15%)
diarrhoea 13.2% (placebo 8.2%)
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.5 mg
nausea 14.8% (placebo 3.6%)
back pain 9.2% (placebo 7.1%)
viral upper respiratory tract infection 6.3% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
0.75 mg
diarrhoea 9.9% (placebo 2.9%)
back pain 8.5% (placebo 7.1%)
viral upper respiratory tract infection 5.7% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
nausea 12% (placebo 1.3%)
diarrhoea 11.3% (placebo 4%)
upper respiratory tract infection 7.3% (placebo 6.7%)
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
hyperlipidaemia 17.8%
diarrhoea 16.7%
lipase increased 10.5%
NCT01648582 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 19.5%
diarrhoea 10.9%
hypertension 10.9%
NCT01648582 · Phase 3 · registry result, not featured evidence
nausea 10.5% (placebo 0%)
diarrhoea 8.4% (placebo 0%)
eructation 5.9% (placebo 0%)
NCT01769378 · Phase 3 · registry result, not featured evidence
1.5 mg
diarrhoea 17.2%
hyperlipidaemia 11.1%
nausea 10.2%
NCT01644500 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 12.1%
diarrhoea 7.3%
lipase increased 5.6%
NCT01644500 · Phase 3 · registry result, not featured evidence
1.5 mg weekly
nausea 20.4%
diarrhoea 12%
dyspepsia 8%
NCT01624259 · Phase 3 · registry result, not featured evidence
4.5 mg
nausea 30.3% (placebo 4.9%)
diarrhoea 21.1% (placebo 11.1%)
vomiting 13.2% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 25.3% (placebo 4.9%)
diarrhoea 22.8% (placebo 11.1%)
decreased appetite 16.5% (placebo 1.2%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
nausea 22.2% (placebo 4.9%)
diarrhoea 11.1% (placebo 11.1%)
vomiting 11.1% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
blood pressure decreased 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
1.5 mg
abdominal discomfort 10% (placebo 6.3%)
decreased appetite 10% (placebo 0%)
nausea 10% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
abdominal discomfort 9.1% (placebo 6.3%)
nausea 9.1% (placebo 0%)
vomiting 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal distension 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
abdominal discomfort 0% (placebo 6.3%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal pain 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
headache 41.2%
nausea 41.2%
vomiting 35.3%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 8%
haemorrhoids 4%
injection site pain 4%
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
vomiting 11.5%
decreased appetite 7.7%
headache 7.7%
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
gastrooesophageal reflux disease 33.3%
atrioventricular block first degree 28.6%
headache 28.6%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dulaglutide

MACE 3-point Composite 13.1% (n=6579) vs 12.2% (n=6586) Tirzepatide @ 259wk1.5 mg
event count · % of participants
NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 862 participants as posted
show 1 more result
12% (n=4949) vs 13.4% (n=4952) placebo*
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 594 Participants as posted
Microvascular Composite 22.2% (n=4949) vs 25.1% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 1099 Participants as posted
HF Hospitalization or Urgent Visit 4.3% (n=4949) vs 4.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted
Unstable Angina Hospitalization 1.8% (n=4949) vs 1.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted
HbA1c -1.4% (n=66) vs -0.44% (n=70) placebo @ 18wk4.5 mg
absolute change · percentage points
NCT02973100 · Phase 2 · registry result, not featured evidence
show 25 more results
-1.31% (n=73) vs -0.44% (n=70) placebo @ 18wk3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
-1.19% (n=138) vs -1.13% (n=175) Insulin Glargine @ 26wk1.5 mg
NCT01621178 · Phase 3
-1.1% (n=130) vs -1% (n=153) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
-1% (n=50) vs 0.5% (n=45) placebo @ 26wk1.5 mg
NCT02963766 · Phase 3
-0.88% (n=6579) vs -1.66% (n=6586) Tirzepatide @ 156wk1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
-2.03% (n=133) vs -1.08% (n=142) placebo @ 28wk1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
-1.34% (n=132) vs -0.54% (n=133) placebo @ 24wk1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
-1.33% (n=130) vs -0.51% (n=123) placebo @ 24wk1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
-1.73% (n=253) vs -1.16% (n=250) Insulin Glargine @ 26wk1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.47% (n=253) vs -0.89% (n=250) Insulin Glargine @ 52wk1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.48% (n=239) vs -0.92% (n=242) Glimepiride @ 26wk1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
-1.42% (n=279) vs -1.36% (n=272) Liraglutide @ 26wk1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
-1.23% (n=73) vs -0.44% (n=70) placebo @ 18wk1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
-1.12% (n=149) vs -1.13% (n=175) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
-1.1% (n=132) vs -1% (n=153) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
-0.5% (n=50) vs 0.5% (n=45) placebo @ 26wk0.75 mg
NCT02963766 · Phase 3
-1.21% (n=134) vs -0.54% (n=133) placebo @ 24wk0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
-1.19% (n=131) vs -0.51% (n=123) placebo @ 24wk0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
-1.33% (n=252) vs -1.16% (n=250) Insulin Glargine @ 26wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.03% (n=252) vs -0.89% (n=250) Insulin Glargine @ 52wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.22% (n=239) vs -0.92% (n=242) Glimepiride @ 26wk0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
-1.44% (n=178) vs -0.9% (n=179) Insulin Glargine @ 26wk
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.45% (n=120) vs 0.06% (n=39) placebo @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
-1.44% (n=150) vs -0.67% (n=150) placebo @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
-1.38% (n=215) vs -0.11% (n=53) placebo @ 24wk
NCT01769378 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 51.1% (n=178) vs 24% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <=6.5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 71.3% (n=178) vs 45.8% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
FBG -34.3 vs -37.8 Insulin Glargine mg @ 26wk
absolute change · mg
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
Weight -4.1 vs -1.6 placebo kg @ 18wk4.5 mg
absolute change · kg
NCT02973100 · Phase 2 · registry result, not featured evidence
show 18 more results
-3.9 vs -1.6 placebo kg @ 18wk3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
-2.81 vs 1.11 Insulin Glargine kg @ 26wk1.5 mg
NCT01621178 · Phase 3
-2.66 vs 1.57 Insulin Glargine kg @ 52wk1.5 mg
NCT01621178 · Phase 3
-0.76 vs 0.42 placebo kg @ 28wk1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
-1.47 vs 0.97 Insulin Glargine kg @ 26wk1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.08 vs 1.35 Insulin Glargine kg @ 52wk1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.46 vs 0.89 Glimepiride kg @ 26wk1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.61 Liraglutide kg @ 26wk1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.6 placebo kg @ 18wk1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
-2.02 vs 1.11 Insulin Glargine kg @ 26wk0.75 mg
NCT01621178 · Phase 3
-1.71 vs 1.57 Insulin Glargine kg @ 52wk0.75 mg
NCT01621178 · Phase 3
-0.88 vs 0.97 Insulin Glargine kg @ 26wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-0.76 vs 1.35 Insulin Glargine kg @ 52wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-0.77 vs 0.89 Glimepiride kg @ 26wk0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
-0.48 vs 0.94 Insulin Glargine kg @ 26wk
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.2 vs -0.3 placebo kg @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
-1.91 vs 0.5 placebo kg @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
-0.91 vs -0.24 placebo kg @ 24wk
NCT01769378 · Phase 3 · registry result, not featured evidence
HbA1c -1.87% (n=526) @ 36wk4.5 mg
absolute change · percentage points
No placebo or comparator arm
NCT03495102 · Phase 3
show 6 more results
-1.71% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
-1.53% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3
-1.53% (n=383) @ 26wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-1.5% (n=383) @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-1.25% (n=193) @ 26wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-1.19% (n=193) @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
Weight -4.7 kg @ 36wk4.5 mg
absolute change · kg
No placebo or comparator arm
NCT03495102 · Phase 3
show 4 more results
-4 kg @ 36wk3 mg
NCT03495102 · Phase 3
-3.1 kg @ 36wk1.5 mg
NCT03495102 · Phase 3
-0.5 kg @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-0.2 kg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 71.48% (n=526) @ 36wk4.5 mg
responder rate · % of participants
No placebo or comparator arm
NCT03495102 · Phase 3
show 2 more results
64.68% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
56.98% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3

+ 65 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · dulaglutide's landscape